Randomized Study of Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT00392665

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:36.650425+00:00

Published At

2017-03-14T00:00:00+00:00

Record Updated At

2017-04-13

Results Posted At

2017-03-14

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Squamous Cell Carcinoma of the Head and Neck (SCCHN)"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2017-04-13"

protocolSection.identificationModule.nctId

"NCT00392665"

protocolSection.identificationModule.officialTitle

"Randomized Study of Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2017-03-14"

Study condition terms

• Squamous Cell Carcinoma of the Head and Neck (SCCHN) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.